Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company (HZNP) Stock Overview
Explore Horizon Therapeutics Public Limited Company’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
26.6B
P/E Ratio
51.10
EPS (TTM)
$1.88
ROE
0.11%
HZNP Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Horizon Therapeutics Public Limited Company (HZNP) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $129.18.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 51.10 and a market capitalization of 26.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.